secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001193125-23-164027
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx shareholders elect two Class II directors and ratify Deloitte as auditor
-------------------------------------------------------------------------------

- George Mclean Milne Jr. and Paul Fonteyne elected as Class II directors; term until 2026.
- Milne received 44,362,315 votes for, 9,410,140 withheld; Fonteyne 44,736,816 for, 9,035,639 withheld.
- Ratification of Deloitte & Touche as independent auditor for FY 2023 passed with 57,585,098 votes for.
- No other matters were submitted to or voted on at the annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312523164027/0001193125-23-164027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312523164027/d501159d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-164027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer